These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25002283)

  • 21. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal management of patients with chronic hepatitis C and comorbidities.
    Boccaccio V; Bruno S
    Liver Int; 2015 Jan; 35 Suppl 1():35-43. PubMed ID: 25529086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 24. Directly acting antivirals against hepatitis C virus.
    Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
    Gellad ZF; Reed SD; Muir AJ
    Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease.
    Lens S; Mariño Z; Forns X
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S197-205. PubMed ID: 25458782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Editorial commentary: Hepatitis C].
    Pár A
    Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
    [No Abstract]   [Full Text] [Related]  

  • 30. [New antivirals against hepatitis C virus(protease inhibitors, polymerase inhibitors, and host factor targeting antivirals)].
    Kato N; Muroyama R
    Nihon Rinsho; 2011 May; 69 Suppl 4():275-81. PubMed ID: 22096931
    [No Abstract]   [Full Text] [Related]  

  • 31. The science of direct-acting antiviral and host-targeted agent therapy.
    Pawlotsky JM
    Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
    Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is hepatitis C virus eradication around the corner only 25 years after its discovery?
    Ippolito G; Capobianchi MR; Lanini S; Antonelli G
    Int J Antimicrob Agents; 2015 Feb; 45(2):111-2. PubMed ID: 25249016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C treatment – yesterday, tomorrow and ….
    Weitzel C
    Med Monatsschr Pharm; 2017 Apr; 40(4):147-50. PubMed ID: 29952162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in and the future of treatments for hepatitis C.
    Cheng R; Tu T; Shackel N; McCaughan GW
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):633-47. PubMed ID: 24846594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.